2014-专业外语讲座-1.ppt

Bioscience Reading and Writing in English,Wei SHIJilin UniversityQQ群：368834154（生科院专业外语课）E.mail:Tel.18686638903,IntroductionArrangementHow to read paper?How to prepare research?Stem cell research DVD riew,Introduction,What is English?Why we must learn English?,What is English?It is only a tool.Why we must learn English?,What is English?It is only a tool.Why we must learn English?,What is English?It is only a tool.Why we must learn English?For science level,信息交流文献是的媒体、语言是工具,语言在民族文化发展的贡献与冲突（例）：印度：殖民统治/英文对社会的影响；日本：对外来文化的态度拿来主义；非洲：民族文化的萎缩；中国：英文会影响我们的传统文化吗？,Lecture Arrangement,Book TeachersCourse,生物学英语与写作,于湘晖 吴永革 刘永新 李青山 编,How to read paper？,Intensive reading and extensive reading,The method for faster reading,Reading more and more（to make a nice custom for reading english article every day）VocabularyNo translation,TitleAbstractBackgroundResultsDiscussion,TitleAbstractBackgroundResultsDiscussion,Title,Understanding 80%from title,Cloning of the variable region genes from hybridoma against HAAH and then construction and expression of anti-HAAH scFv.,Cloning of the variable region genes from hybridoma against HAAH and then construction and expression of anti-HAAH scFv.,Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi.2010 May;26(5):467-70.Cloning of the variable region genes from hybridoma against HAAH and then construction and expression of anti-HAAH scFv.Article in ChineseWang H,Xue XP,Lei YF,Song K,Hu YT,Wang W,Yang H.Faculty of Life Sciences,Northwestern Polytechnical University,Xian 710072,China.AbstractAIM:Construction and expression of anti-HAAH single chain variable fragment(scFv)by cloning of the variable region genes from anti-HAAH hybridoma cells G3/F11.METHODS:Total RNA was extracted from hybridoma cells G3/F11.By RT-PCR,murine V(H);and V(L);genes of mAb were amplified respectively.Then,They were assembled into V(H);-linker-V(L);scFv template by SOE-PCR and anti-HAAH scFv was express in E.coli by constructed pHEN 1-Anti-HAAH vector.The expression of Anti-HAAH scFv were detected by SDS-PAGE and Western blotting and the binding activity were demonstrated by ELISA.RESULTS:The analysis of DNA sequencing shown that the full-length of constructed scFv gene was 744 bp,encoding 248 amino acids.Moreover,the V(H);and V(L);genes were functional antibody variable region genes,as there were four FRs and three CDRs in both of them.By SDS-PAGE and Western blotting,the expression level of Anti-HAAH scFv were detected.The expression level of pHEN 1-Anti-HAAH scFv,which was expressed in E.coli HB2151,was 7.8%in total E.coli protein and were existed in soluble protein mainly.By indirect ELISA detcetion with HAAH protein,the binding activity of soluble anti-HAAH scFv was very well.CONCLUSION:The murine V(H);and V(L);genes of mAb against HAAH have been cloned successfully and anti-HAAH scFv have been constructed and expressed.Besides,the scFv could be further studied about their biological activity and application,due to their high affinity shown in preliminary detection.,Preparation of monoclonal antibodies against HN protein of ClassI Newcastle disease virus virulent strain.,Preparation of monoclonal antibodies against HN protein of ClassI Newcastle disease virus virulent strain.,Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi.2010 May;26(5):464-6.Preparation of monoclonal antibodies against HN protein of ClassI Newcastle disease virus virulent strain.Article in ChineseSun YJ,Chen HJ,Song CP,Yu Y,Qiu XS,Yu SQ,Ding C.Shanghai Veterinary Research Institute,Chinese Academy of Agricultural Sciences,Shanghai 200241,China.AbstractAIM:To prepare monoclonal antibodies(mAb)against HN protein of Class I Newcaslte disease virus.METHODS:Several 6-week-old mice were immunized with ClassI 9a5b virulent strain.Hemagglutination inhibition(HI),indirect immunofluorescence assay(IFA),cell neutralization test,ELISA and Western blot analysis were used to characterize and identify these antibodies.RESULTS:Four hybridoma cell lines were successfully prepared,designated as mAb 2F5,2F12,3H7 and 3H9.Among them,only mAb 3H7 and 3H9 recognized HN protein of the ClassI strain,specifically neutralizing NDV and inhibiting hemagglutination.CONCLUSION:mAb 3H7 and 3H9 could be of use in identification of Class I and Class II strains,and in functional studies of HN and cell receptors for NDV.PMID:20423654 PubMed-in process,EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.,EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.,Expert Opin Emerg Drugs.2010 Apr 23.Epub ahead of printEGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.Sundvall M,Karrila A,Nordberg J,Grnman R,Elenius K.University of Turku,Department of Medical Biochemistry and Genetics,MediCity Research Laboratories,FIN-20520 Turku,Finland.AbstractImportance of the field:Head and neck cancer is the sixth most common cancer worldwide.Despite intense efforts to improve different treatment modalities,mortality rates in advanced cases remain high.Areas covered in the review:EGFR targeting mAb cetuximab(Erbitux)has been approved for the treatment of locally advanced head and neck squamous cell carcinoma(HNSCC)in combination with radiotherapy and for recurrent or metastatic HNSCC.Here,we review recent scientific advances,as well as future research goals regarding EGFR inhibitors in the treatment of HNSCC.Information was compiled by searching the PubMed,Web of Knowledge and American Society of Clinical Oncology databases for articles published before October 2009.The search terms included head and neck cancer,EGFR,cetuximab,panitumumab,zalutumumab,nimotuzumab,erlotinib,gefitinib and lapatinib.The National Institutes of Health registry of clinical trials(www.clinicaltrials.gov)was used to search for clinical trials in HNSCC.What the reader will gain:The background scientific rationale,clinical efficacy and development of EGFR inhibitors in HNSCC are discussed.Take home message:Cetuximab significantly improves survival of patients with locally advanced or metastatic HNSCC.Treatment strategies combining EGFR inhibitors with multimodality approaches may eventually increase cure rate in HNSCC.,Reading Abstracts,AbstractOBJECTIVE:Antigen-specific therapy targeting selective inhibition of autoreactive responses holds promise for controlling multiple sclerosis(MS)without disturbing homeostasis of the whole immune system.Key autoantigens in MS include myelin proteins,such as myelin basic protein(MBP),proteolipid protein(PLP),and myelin oligodendrocyte glycoprotein(MOG).In this study,we examined the effect of transdermal therapy with myelin peptides on immune responses in the skin,lymph nodes,and peripheral blood immune cells of MS patients.METHODS:In a 1-year placebo-controlled study,30 patients with relapsing-remitting MS were treated transdermally with a mixture of 3 myelin peptides:MBP85-99,PLP139-151,and MOG35-55,or placebo.The phenotype of immune cells in the skin was assessed using immunohistochemistry.Cell populations in lymph nodes were analyzed using flow cytometry.In peripheral blood immune cells,cytokine production was measured by enzyme-linked immunosorbent assay,and myelin-specific proliferation was examined by carboxyfluorescein succinimidyl ester-based assay.RESULTS:We found that myelin peptides applied transdermally to MS patients activated dendritic Langerhans cells in the skin at the site of immunization and induced a unique population of granular dendritic cells in local lymph nodes.In the periphery,transdermal immunization with myelin peptides resulted in the generation of type 1,interleukin-10-producing regulatory T cells,suppression of specific autoreactive proliferative responses,and suppression of interferon-and transforming growth factor-production.,AbstractOBJECTIVE:Antigen-specific therapy targeting selective inhibition of autoreactive responses holds promise for controlling multiple sclerosis(MS)without disturbing homeostasis of the whole immune system.Key autoantigens in MS include myelin proteins,such as myelin basic protein(MBP),proteolipid protein(PLP),and myelin oligodendrocyte glycoprotein(MOG).In this study,we examined the effect of transdermal therapy with myelin peptides on immune responses in the skin,lymph nodes,and peripheral blood immune cells of MS patients.METHODS:In a 1-year placebo-controlled study,30 patients with relapsing-remitting MS were treated transdermally with a mixture of 3 myelin peptides:MBP85-99,PLP139-151,and MOG35-55,or placebo.The phenotype of immune cells in the skin was assessed using immunohistochemistry.Cell populations in lymph nodes were analyzed using flow cytometry.In peripheral blood immune cells,cytokine production was measured by enzyme-linked immunosorbent assay,and myelin-specific proliferation was examined by carboxyfluorescein succinimidyl ester-based assay.RESULTS:We found that myelin peptides applied transdermally to MS patients activated dendritic Langerhans cells in the skin at the site of immunization and induced a unique population of granular dendritic cells in local lymph nodes.In the periphery,transdermal immunization with myelin peptides resulted in the generation of type 1,interleukin-10-producing regulatory T cells,suppression of specific autoreactive proliferative responses,and suppression of interferon-and transforming growth factor-production.,Immune regulation of multiple sclerosis by transdermally applied myelin peptides,AbstractHuman epidermal growth factor(hEGF)induces the proliferation,differentiation and survival of various cell types including tumor-derived cells.Generally,hEGF performs its biological function by binding to a specific receptor(hEGFR)on the cell surface,thereby inducing signal transduction.Suramin,a polysulfonated naphthylurea that acts as a growth factor blocker,exhibits antiproliferative activity against non-small cell lung cancer(NSCLC)cells that overexpress EGFR on the cell surface.We determined the solution structure of hEGF under physiological conditions and investigated the interaction of suramin with hEGF using isothermal titration calorimetry and NMR spectroscopy techniques.The solution structure of hEGF presented in this paper is different from the bound form of hEGF present in the crystal structure of the 2:2 EGF-EGFR complex because its C-tail contains a hydrophobic core.This conformational difference supports the hypothesis that hEGF undergoes a conformational change when it binds to hEGFR and subsequently induces signal transduction.Based on the docking structure of the hEGF-suramin complex,we demonstrated how suramin blocks hEGF by binding to its receptor binding site(the C-terminal region around Arg45)and inhibits the crucial conformational change.,The NMR solution structure of human epidermal growth factor(hEGF)at physiological pH and its interactions with suramin.,